4XGQ image
Deposition Date 2015-01-02
Release Date 2015-08-12
Last Version Date 2024-03-20
Entry Detail
PDB ID:
4XGQ
Keywords:
Title:
Crystal structure of addiction module from Mycobacterial species
Biological Source:
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 31 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Ribonuclease VapC30
Gene (Uniprot):vapC30
Chain IDs:A, C (auth: E), E (auth: C), G
Chain Length:132
Number of Molecules:4
Biological Source:Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Antitoxin VapB30
Gene (Uniprot):vapB30
Chain IDs:B, D (auth: F), F (auth: D), H
Chain Length:84
Number of Molecules:4
Biological Source:Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Ligand Molecules
Primary Citation
Structural and functional studies of the Mycobacterium tuberculosis VapBC30 toxin-antitoxin system: implications for the design of novel antimicrobial peptides
Nucleic Acids Res. 43 7624 7637 (2015)
PMID: 26150422 DOI: 10.1093/nar/gkv689

Abstact

Toxin-antitoxin (TA) systems play important roles in bacterial physiology, such as multidrug tolerance, biofilm formation, and arrest of cellular growth under stress conditions. To develop novel antimicrobial agents against tuberculosis, we focused on VapBC systems, which encompass more than half of TA systems in Mycobacterium tuberculosis. Here, we report that theMycobacterium tuberculosis VapC30 toxin regulates cellular growth through both magnesium and manganese ion-dependent ribonuclease activity and is inhibited by the cognate VapB30 antitoxin. We also determined the 2.7-Å resolution crystal structure of the M. tuberculosis VapBC30 complex, which revealed a novel process of inactivation of the VapC30 toxin via swapped blocking by the VapB30 antitoxin. Our study on M. tuberculosis VapBC30 leads us to design two kinds of VapB30 and VapC30-based novel peptides which successfully disrupt the toxin-antitoxin complex and thus activate the ribonuclease activity of the VapC30 toxin. Our discovery herein possibly paves the way to treat tuberculosis for next generation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures